Announcements
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)
- Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
- Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting
- Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers
- Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors
- Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres
- Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)
- Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio
- Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 12.75 |
Average volume | -- |
---|---|
Shares outstanding | 93.92m |
Free float | 87.73m |
P/E (TTM) | -- |
Market cap | 27.24m EUR |
EPS (TTM) | -0.9993 EUR |
Data delayed at least 15 minutes, as of Aug 02 2018.
More ▼